![Tim Knotnerus](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tim Knotnerus
Directeur Général chez
AGOMAB THERAPEUTICS NV
Fortune : 508 691 $ au 31/05/2026
Profil
Tim Knotnerus is currently Chief Executive Officer & Executive Director at AgomAb Therapeutics NV since 2021, with employment at the firm starting in 2019.
Formerly, Dr. Knotnerus was Vice President-Corporate Development at AM-Pharma BV from 2012 to 2020 and Senior Associate at Aescap Venture Management BV from 2011 to 2012.
Dr. Knotnerus completed an MBA at the International Institute for Management Development.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AGOMAB THERAPEUTICS NV 0,09 % | 18/03/2026 | 45 217 ( 0,09 % ) | 508 691 $ | 31/05/2026 |
Postes actifs de Tim Knotnerus
| Sociétés | Poste | Début |
|---|---|---|
| AGOMAB THERAPEUTICS NV | Directeur Général | 01/02/2019 |
Anciens postes connus de Tim Knotnerus
| Sociétés | Poste | Fin |
|---|---|---|
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology Provides biopharmaceutical products | Corporate Officer/Principal | 01/04/2020 |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure. | Analyste en capital-investissement | 31/05/2012 |
Formation de Tim Knotnerus
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
6
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
International Institute for Management Development
 International Institute for Management Development Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure. | Finance |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology Provides biopharmaceutical products | Health Technology |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
